Cargando…

Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens

Eimeria maxima (E. maxima) is one of the most prevalent species that causes chicken coccidiosis on chicken farms. During apicomplexan protozoa invasion, rhomboid-like proteins (ROMs) cleave microneme proteins (MICs), allowing the parasites to fully enter the host cells, which suggests that ROMs have...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Di, Liu, Xiaoqian, Li, Xiangrui, Xu, Lixin, Yan, Ruofeng, Song, Xiaokai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781051/
https://www.ncbi.nlm.nih.gov/pubmed/35062693
http://dx.doi.org/10.3390/vaccines10010032
_version_ 1784637994024566784
author Tian, Di
Liu, Xiaoqian
Li, Xiangrui
Xu, Lixin
Yan, Ruofeng
Song, Xiaokai
author_facet Tian, Di
Liu, Xiaoqian
Li, Xiangrui
Xu, Lixin
Yan, Ruofeng
Song, Xiaokai
author_sort Tian, Di
collection PubMed
description Eimeria maxima (E. maxima) is one of the most prevalent species that causes chicken coccidiosis on chicken farms. During apicomplexan protozoa invasion, rhomboid-like proteins (ROMs) cleave microneme proteins (MICs), allowing the parasites to fully enter the host cells, which suggests that ROMs have the potential to be candidate antigens for the development of subunit or DNA vaccines against coccidiosis. In this study, a recombinant protein of E. maxima ROM5 (rEmROM5) was expressed and purified and was used as a subunit vaccine. The eukaryotic expression plasmid of pVAX–EmROM5 was constructed and was used as a DNA vaccine. Chickens who were two weeks old were vaccinated with the rEmROM5 and pVAX–EmROM5 vaccines twice, with a one-week interval separating the vaccination periods. The transcription and expression of pVAX–EmROM5 in the injected sites were detected through reverse transcription PCR (RT-PCR) and Western blot (WB) assays. The cellular and humoral immune responses that were induced by EmROM5 were determined by detecting the proportion of CD4(+) and CD8(+) T lymphocytes, the cytokine levels, and the serum antibody levels. Finally, vaccination-challenge trials were conducted to evaluate the protective efficacy of EmROM5 in forms of the recombinant protein (rEmROM5) and in the DNA plasmid (pVAX–EmROM5) separately. The results showed that rEmROM5 was about 53.64 kDa, which was well purified and recognized by the His-Tag Mouse Monoclonal antibody and the chicken serum against E. maxima separately. After vaccination, pVAX–EmROM5 was successfully transcribed and expressed in the injected sites of the chickens. Vaccination with rEmROM5 or pVAX–EmROM5 significantly promoted the proportion of CD4(+)/CD3(+) and CD8(+)/CD3(+) T lymphocytes, the mRNA levels of the cytokines IFN-γ, IL-2, IL-4, IL-17, TNF SF15, and IL-10, and specific IgG antibody levels compared to the control groups. The immunization also significantly reduced the weight loss, oocyst production, and intestinal lesions that are caused by E. maxima infection. The anticoccidial index (ACI)s of the vaccinated groups were beyond 160, showing moderate protection against E. maxima infection. In summary, EmROM5 was able to induce a robust immune response and effective protection against E. maxima in chickens in the form of both a recombinant protein and DNA plasmid. Hence, EmROM5 could be used as a candidate antigen for DNA vaccines and subunit vaccines against avian coccidiosis.
format Online
Article
Text
id pubmed-8781051
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87810512022-01-22 Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens Tian, Di Liu, Xiaoqian Li, Xiangrui Xu, Lixin Yan, Ruofeng Song, Xiaokai Vaccines (Basel) Article Eimeria maxima (E. maxima) is one of the most prevalent species that causes chicken coccidiosis on chicken farms. During apicomplexan protozoa invasion, rhomboid-like proteins (ROMs) cleave microneme proteins (MICs), allowing the parasites to fully enter the host cells, which suggests that ROMs have the potential to be candidate antigens for the development of subunit or DNA vaccines against coccidiosis. In this study, a recombinant protein of E. maxima ROM5 (rEmROM5) was expressed and purified and was used as a subunit vaccine. The eukaryotic expression plasmid of pVAX–EmROM5 was constructed and was used as a DNA vaccine. Chickens who were two weeks old were vaccinated with the rEmROM5 and pVAX–EmROM5 vaccines twice, with a one-week interval separating the vaccination periods. The transcription and expression of pVAX–EmROM5 in the injected sites were detected through reverse transcription PCR (RT-PCR) and Western blot (WB) assays. The cellular and humoral immune responses that were induced by EmROM5 were determined by detecting the proportion of CD4(+) and CD8(+) T lymphocytes, the cytokine levels, and the serum antibody levels. Finally, vaccination-challenge trials were conducted to evaluate the protective efficacy of EmROM5 in forms of the recombinant protein (rEmROM5) and in the DNA plasmid (pVAX–EmROM5) separately. The results showed that rEmROM5 was about 53.64 kDa, which was well purified and recognized by the His-Tag Mouse Monoclonal antibody and the chicken serum against E. maxima separately. After vaccination, pVAX–EmROM5 was successfully transcribed and expressed in the injected sites of the chickens. Vaccination with rEmROM5 or pVAX–EmROM5 significantly promoted the proportion of CD4(+)/CD3(+) and CD8(+)/CD3(+) T lymphocytes, the mRNA levels of the cytokines IFN-γ, IL-2, IL-4, IL-17, TNF SF15, and IL-10, and specific IgG antibody levels compared to the control groups. The immunization also significantly reduced the weight loss, oocyst production, and intestinal lesions that are caused by E. maxima infection. The anticoccidial index (ACI)s of the vaccinated groups were beyond 160, showing moderate protection against E. maxima infection. In summary, EmROM5 was able to induce a robust immune response and effective protection against E. maxima in chickens in the form of both a recombinant protein and DNA plasmid. Hence, EmROM5 could be used as a candidate antigen for DNA vaccines and subunit vaccines against avian coccidiosis. MDPI 2021-12-27 /pmc/articles/PMC8781051/ /pubmed/35062693 http://dx.doi.org/10.3390/vaccines10010032 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tian, Di
Liu, Xiaoqian
Li, Xiangrui
Xu, Lixin
Yan, Ruofeng
Song, Xiaokai
Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title_full Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title_fullStr Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title_full_unstemmed Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title_short Eimeria maxima Rhomboid-like Protein 5 Provided Partial Protection against Homologous Challenge in Forms of Recombinant Protein and DNA Plasmid in Chickens
title_sort eimeria maxima rhomboid-like protein 5 provided partial protection against homologous challenge in forms of recombinant protein and dna plasmid in chickens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781051/
https://www.ncbi.nlm.nih.gov/pubmed/35062693
http://dx.doi.org/10.3390/vaccines10010032
work_keys_str_mv AT tiandi eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens
AT liuxiaoqian eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens
AT lixiangrui eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens
AT xulixin eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens
AT yanruofeng eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens
AT songxiaokai eimeriamaximarhomboidlikeprotein5providedpartialprotectionagainsthomologouschallengeinformsofrecombinantproteinanddnaplasmidinchickens